WASHINGTON, May 26, 2020 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that
Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020
Annual Meeting") in a virtual-only format due to public health
concerns related to the COVID-19 pandemic and to protect the health
and well-being of its stockholders, directors, employees and the
public. As previously announced, the 2020 Annual Meeting will be
held on June 11, 2020, at
9:00 a.m. Eastern Time.
Stockholders will not be able to attend the 2020 Annual Meeting
in-person at a physical location. However, the virtual 2020 Annual
Meeting will provide stockholders of record as of the close of
business on April 17, 2020 the
ability to vote their shares and submit questions during the
meeting via the virtual meeting interface.
If you have already submitted a proxy to vote your shares, your
shares will be voted at the 2020 Annual Meeting according to your
instructions and you do not need to vote your shares at the 2020
Annual Meeting. Stockholders are encouraged to vote in advance of
the 2020 Annual Meeting by telephone, through the Internet or by
returning the proxy card or voting instruction card previously
received with their proxy materials (as described more fully in
Vanda's proxy statement made available to stockholders on
April 22, 2020 (the "Proxy
Statement") and available Vanda's website at www.vandapharma.com
and www.proxyvote.com).
If you are a stockholder of record, to gain access to the
virtual Meeting go to www.virtualshareholdermeeting.com/VNDA2020.
To be admitted to the 2020 Annual Meeting webcast at the website
provided above, you will need the 16-digit control number included
on your proxy card or Notice of Internet Availability of
Proxy Materials (the "Notice"). Beneficial owners of shares held in
street name will need to follow the instructions provided by the
broker, bank or other nominee that holds their shares (as described
more fully in the Proxy Statement and available Vanda's website at
www.vandapharma.com and www.proxyvote.com). Only one stockholder
per 16-digit control number can access the virtual 2020 Annual
Meeting at the website set forth above. Vanda encourages
stockholders to log-in to this website and access the webcast
before the virtual 2020 Annual Meeting start time.
Below are additional details on how stockholders can participate
in the 2020 Annual Meeting:
- Access the meeting platform beginning at 8:45 a.m. Eastern Time on June 11, 2020.
- Once admitted, stockholders of record may submit questions or
votes during the Meeting by following the instructions that will be
available on the meeting website.
- To attend the meeting, you will need the 16-digit control
number located on your proxy card or Notice.
A complete list of stockholders entitled to vote at the 2020
Annual Meeting will be open to the examination of any stockholder
during the meeting by following the instructions on the 2020 Annual
Meeting website once they enter the virtual meeting.
If you encounter any difficulties accessing the virtual meeting
during the check-in or meeting time, please call the technical
support number (800) 586-1548 (US) or (303) 562-9288 (Outside the
US). This number will also be posted on the 2020 Annual Meeting
log-in page. Technical support will be available beginning at
8:45 a.m. Eastern Time on
June 11, 2020 and will remain
available until the meeting has ended. Digital copies of the
Proxy Statement and Vanda's annual report on Form 10-K for the year
ended December 31, 2019 are available
at www.proxyvote.com. These materials also are available on Vanda's
website at www.vandapharma.com.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Vanda's Twitter and
LinkedIn.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release relating to the 2020 Annual
Meeting may be "forward-looking statements" under the securities
laws. Forward-looking statements are based upon current
expectations that involve risks, changes in circumstances,
assumptions and uncertainties. Important factors relating to
Vanda's ability to complete the virtual 2020 Annual Meeting
include, among others, logistical and administrative issues arising
with the hosting of a virtual stockholder meeting, imposition of
restrictive governmental regulations implemented to address public
health concerns, or operational delays or difficulties because of
COVID-19 (or uncertainty regarding the same) and other factors
described in the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of Vanda's annual report on Form 10-K for the fiscal year ended
December 31, 2019 and quarterly
report on Form 10-Q for the quarter ended March 31, 2020, which are on file with the SEC
and available on the SEC's website at www.sec.gov. In addition to
the risks described above and in Vanda's annual report on Form 10-K
and quarterly reports on Form 10-Q, other unknown or unpredictable
factors also could affect Vanda's results. There can be no
assurance that the actual results or developments anticipated by
Vanda will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Vanda.
Therefore, no assurance can be given that the outcomes stated in
such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this release is provided
only as of the date of this release, and Vanda undertakes no
obligation, and specifically declines any obligation, to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Corporate Contact:
AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-virtual-2020-stockholder-meeting-301065031.html
SOURCE Vanda Pharmaceuticals Inc.